Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1987 1
1988 1
1995 3
2002 1
2005 2
2006 2
2007 2
2008 2
2009 6
2010 4
2011 5
2012 3
2014 6
2015 7
2016 3
2017 8
2018 5
2019 9
2020 6
2021 8
2022 15
2023 14
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

98 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
The following terms were ignored: %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %
The following terms were not found in PubMed: 28Hooker, 5BAuthor, 28Hooker, 5BAuthor, 28Hooker, 5BAuthor, 28Placzek, 5BAuthor, 28Placzek, 5BAuthor, 28Zurcher, 5BAuthor, 28Zurcher, 5BAuthor, 28Zurcher, 5BAuthor, 28wang, 5BAuthor, 28Wey, 5BAuthor, 28Wey, 5BAuthor
Page 1
Quality of Life in Patients With Chronic Limb-Threatening Ischemia Treated With Revascularization.
Menard MT, Farber A, Powell RJ, Rosenfield K, Conte MS, Hamza TH, Kaufman JA, Cziraky MJ, Creager MA, Dake MD, Jaff MR, Reid D, Sopko G, White CJ, Strong MB, van Over M, Chisci E, Goodney PP, Gray B, Kayssi A, Siracuse JJ, Choudhry NK; BEST-CLI Investigators. Menard MT, et al. Circulation. 2024 Apr 16;149(16):1241-1253. doi: 10.1161/CIRCULATIONAHA.123.065277. Epub 2024 Apr 10. Circulation. 2024. PMID: 38597097 Free article. Clinical Trial.
HRQoL was assessed over the trial duration using Vascular Quality-of-Life (VascuQoL), European Quality-of-Life-5D (EQ-5D), the Short Form-12 (SF-12) Physical Component Summary (SF-12 PCS), SF-12 Mental Component Summary (SF-12 MCS), Utility Index Score (SF-6D R2), a …
HRQoL was assessed over the trial duration using Vascular Quality-of-Life (VascuQoL), European Quality-of-Life-5D (EQ-5D), the …
Impact of Primary Tumor Location on Demographics, Resectability, Outcomes, and Quality of Life in Finnish Metastatic Colorectal Cancer Patients (Subgroup Analysis of the RAXO Study).
Aho S, Osterlund E, Ristimäki A, Nieminen L, Sundström J, Mäkinen MJ, Kuopio T, Kytölä S, Ålgars A, Ristamäki R, Heervä E, Kallio R, Halonen P, Soveri LM, Nordin A, Uutela A, Salminen T, Stedt H, Lamminmäki A, Muhonen T, Kononen J, Glimelius B, Isoniemi H, Lehto JT, Lehtomäki K, Osterlund P. Aho S, et al. Cancers (Basel). 2024 Mar 5;16(5):1052. doi: 10.3390/cancers16051052. Cancers (Basel). 2024. PMID: 38473410 Free PMC article.
Health-related quality of life (HRQoL) was assessed multi-cross-sectionally with QLQ-C30, QLQ-CR29, EQ-5D, and 15D. A chi-square, Kaplan-Meier, and Cox regression were used to compare the groups. The PTL was in the right colon in 310 patients (29%), the left colon i …
Health-related quality of life (HRQoL) was assessed multi-cross-sectionally with QLQ-C30, QLQ-CR29, EQ-5D, and 15D. A chi-square, Kap …
Treatments for Morton's neuroma.
Matthews BG, Thomson CE, Harding MP, McKinley JC, Ware RS. Matthews BG, et al. Cochrane Database Syst Rev. 2024 Feb 9;2(2):CD014687. doi: 10.1002/14651858.CD014687.pub2. Cochrane Database Syst Rev. 2024. PMID: 38334217 Review.
CS+LA probably results in little to no difference in HRQoL when compared to LA (MD 0.07, 95% CI -0.03 to 0.17; P = 0.19; 1 study, 122 participants; moderate-certainty evidence), and CS+LA may not increase satisfaction (risk ratio (RR) 1.08, 95% CI 0.63 to 1.85; P = 0.78; 1 study, …
CS+LA probably results in little to no difference in HRQoL when compared to LA (MD 0.07, 95% CI -0.03 to 0.17; P = 0.19; 1 study, 122 partic …
Cardiac Rehabilitation Use After Heart Failure Hospitalization Associated With Advanced Heart Failure Center Status.
Thompson MP, Hou H, Fliegner M, Guduguntla V, Cascino T, Aaronson KD, Likosky DS, Sukul D, Keteyian SJ. Thompson MP, et al. J Cardiopulm Rehabil Prev. 2024 Feb 2. doi: 10.1097/HCR.0000000000000846. Online ahead of print. J Cardiopulm Rehabil Prev. 2024. PMID: 38300252
The association between advanced HF status (hospitals performing heart transplantation or ventricular assist device implantations) and CR participation was evaluated with logistic regression, accounting for patient, hospital, and regional factors. RESULTS: Among 143 392 Medicare …
The association between advanced HF status (hospitals performing heart transplantation or ventricular assist device implantations) and CR pa …
Microcrystalline Luminescent (Eu1-xLnx)2bdc3·nH2O (Ln = La, Gd, Lu) Antenna MOFs: Effect of Dopant Content on Structure, Particle Morphology, and Luminescent Properties.
Kolesnik SS, Bogachev NA, Kolesnikov IE, Orlov SN, Ryazantsev MN, González G, Skripkin MY, Mereshchenko AS. Kolesnik SS, et al. Molecules. 2024 Jan 21;29(2):532. doi: 10.3390/molecules29020532. Molecules. 2024. PMID: 38276610 Free PMC article.
The photoluminescence quantum yield and (5)D(0) excited state lifetime of Eu(3+) are equal to 11 2% and 0.44 0.01 ms, respectively, for the Ln(2)bdc(3).4H(2)O structures. For the (Eu(1-x)Lu(x))(2)bdc(3).2.5H(2)O compounds, significant increases in the photoluminescence qua …
The photoluminescence quantum yield and (5)D(0) excited state lifetime of Eu(3+) are equal to 11 2% and 0.44 0.01 ms, respectively, f …
Direct observation of NMR transverse relaxation in nanopatterned clusters of iron oxide particles.
Bok I, Rauch B, Ashtiani A, Hai A. Bok I, et al. Magn Reson Med. 2024 Feb;91(2):687-698. doi: 10.1002/mrm.29898. Epub 2023 Oct 23. Magn Reson Med. 2024. PMID: 37867452
We found negative quadratic relationships (-0.0045[log tau(D) ](2) -0.0655[log tau(D) ]-2.7800) for single nanoparticles of varying sizes and for clusters (-0.0045[log tau(D) ](2) -0.0827[log tau(D) ]-2.3249) for diffusional correlation time tau(D) = r(p) (2) /D. Clusters …
We found negative quadratic relationships (-0.0045[log tau(D) ](2) -0.0655[log tau(D) ]-2.7800) for single nanoparticles of varying sizes an …
Karnofsky Performance Status and quality of life in patients with relapsed or refractory primary CNS lymphoma from a phase I/II study of tirabrutinib.
Arakawa Y, Narita Y, Nagane M, Mishima K, Terui Y, Yonezawa H, Asai K, Fukuhara N, Sugiyama K, Shinojima N, Aoi A, Nishikawa R. Arakawa Y, et al. Neurooncol Adv. 2023 Sep 14;5(1):vdad109. doi: 10.1093/noajnl/vdad109. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37744697 Free PMC article.
METHODS: Patients with r/r PCNSL, age 20 years, and KPS 70 were treated with tirabrutinib once daily at a dose of 320, 480, or 480 mg under fasted conditions. ...CONCLUSIONS: Tirabrutinib generally maintains KPS and QoL scores with some improvements in specific QoL …
METHODS: Patients with r/r PCNSL, age 20 years, and KPS 70 were treated with tirabrutinib once daily at a dose of 320, 480, or …
Strict blood pressure control following thrombectomy is associated with neuronal injury and poor functional outcome.
Hahn M, Hayani E, Bitar L, Gröschel S, Steffen F, Protopapa M, Othman A, Bittner S, Zipp F, Gröschel K, Uphaus T. Hahn M, et al. Ann Clin Transl Neurol. 2023 Dec;10(12):2255-2265. doi: 10.1002/acn3.51909. Epub 2023 Sep 25. Ann Clin Transl Neurol. 2023. PMID: 37743753 Free PMC article.
"low-BP" was associated with unfavorable functional outcome at 90-day follow-up (aOR [95%CI]: 5.88 [1.88-18.32], p = 0.002) and decreased health-related quality of life (mean EQ-5D-index 0.45 0.28 vs 0.63 0.31, p = 0.009). sNfL levels were increased in "low-BP" pati …
"low-BP" was associated with unfavorable functional outcome at 90-day follow-up (aOR [95%CI]: 5.88 [1.88-18.32], p = 0.002) and decreased he …
Psychometric Properties of LUN-MS: A New Questionnaire to Identify the Unmet Needs of People With Multiple Sclerosis.
Mohamed Abu Baker A, Moore H, Baster K, Hobson E, Paling D, Sharrack B, Nair KPS. Mohamed Abu Baker A, et al. Adv Rehabil Sci Pract. 2023 Sep 19;12:27536351231197142. doi: 10.1177/27536351231197142. eCollection 2023 Jan-Dec. Adv Rehabil Sci Pract. 2023. PMID: 37736485 Free PMC article.
BACKGROUND: We developed a 29-item Questionnaire, Long-term Unmet Needs in MS (LUN-MS) to identify the unmet needs of people with multiple sclerosis (pwMS). ...The unmet needs could be divided into five internally consistent domains (Cronbach's alpha 0.83-0.7 …
BACKGROUND: We developed a 29-item Questionnaire, Long-term Unmet Needs in MS (LUN-MS) to identify the unmet needs of p …
Low Correlation between Gait and Quality of Life in Advanced Knee Osteoarthritis.
Freijo V, Navarro C, Molina B, Villalba J. Freijo V, et al. J Funct Morphol Kinesiol. 2023 Jun 8;8(2):77. doi: 10.3390/jfmk8020077. J Funct Morphol Kinesiol. 2023. PMID: 37367241 Free PMC article.

Patients showed a mean walking speed of 0.95 0.19 m/s, a mean cadence of 105.6 9.9 steps/min, and a mean stride length of 1.25 0.17 m on both legs. They presented poor knee status (KSS < 60) and poor QoL, with an EQ-5D of 0.44 0.24 and a total KOOS of 2

…
Patients showed a mean walking speed of 0.95 0.19 m/s, a mean cadence of 105.6 9.9 steps/min, and a mean stride length of 1.25 0.17 …
Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world study.
Gossec L, Siebert S, Bergmans P, de Vlam K, Gremese E, Joven-Ibáñez B, Korotaeva TV, Lavie F, Noël W, Nurmohamed MT, Sfikakis PP, Sharaf M, Theander E, Smolen JS. Gossec L, et al. Arthritis Res Ther. 2023 Jun 23;25(1):109. doi: 10.1186/s13075-023-03058-y. Arthritis Res Ther. 2023. PMID: 37353788 Free PMC article.
METHODS: In PsABio (NCT02627768), a prospective, observational study, patients with PsA that were prescribed first- to third-line ustekinumab or a TNFi, and remained on that drug for 3 years, were analysed for change in baseline in PROs (EuroQol-5 dimensions health state VAS [EQ- …
METHODS: In PsABio (NCT02627768), a prospective, observational study, patients with PsA that were prescribed first- to third-line ustekinuma …
Efficacy of Dimethyl Fumarate in Young Adults with Relapsing-Remitting Multiple Sclerosis: Analysis of the DEFINE, CONFIRM, and ENDORSE Studies.
Amezcua L, Mao-Draayer Y, Vargas WS, Farber R, Schaefer S, Branco F, England SM, Belviso N, Lewin JB, Mendoza JP, Shankar SL; ENDORSE Study Investigators. Amezcua L, et al. Neurol Ther. 2023 Jun;12(3):883-897. doi: 10.1007/s40120-023-00475-8. Epub 2023 Apr 15. Neurol Ther. 2023. PMID: 37061656 Free PMC article.
INTRODUCTION: Dimethyl fumarate (DMF) showed favorable benefit-risk in patients with relapsing-remitting multiple sclerosis (MS) in phase 3 DEFINE and CONFIRM trials and in the ENDORSE extension study. ...At ~ 7 years, the proportion of young adults with no confirmed disab …
INTRODUCTION: Dimethyl fumarate (DMF) showed favorable benefit-risk in patients with relapsing-remitting multiple sclerosis (MS) in p …
Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis.
Ryerson LZ, Foley JF, Defer G, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Sinks S, Kuhelj R, Bodhinathan K, Lasky T. Ryerson LZ, et al. Mult Scler Relat Disord. 2023 Apr;72:104561. doi: 10.1016/j.msard.2023.104561. Epub 2023 Feb 11. Mult Scler Relat Disord. 2023. PMID: 36931078 Free article. Clinical Trial.
Similarly, there were no significant differences between Q6W and Q4W groups in LSM change from baseline for any PRO (TSQM, -1.00, P = 0.410; Neuro-QoL fatigue, 0.52, P = 0.292; MSIS-29 Psychological, 0.67, P = 0.572; MSIS-29 Physical, 0.74, P = 0.429; EQ-5D-5 …
Similarly, there were no significant differences between Q6W and Q4W groups in LSM change from baseline for any PRO (TSQM, -1.00, P = 0.410; …
A Prospective, Observational Study Assessing Effectiveness, Safety, and QoL of Greek Patients with Multiple Sclerosis Under Treatment with Fingolimod.
Mitsikostas DD, Orologas A, Dardiotis E, Fakas N, Doskas T, Karageorgiou K, Maltezou M, Iliopoulos I, Vikelis M, Grigoriadis N. Mitsikostas DD, et al. Adv Ther. 2023 May;40(5):2217-2233. doi: 10.1007/s12325-022-02388-8. Epub 2023 Mar 10. Adv Ther. 2023. PMID: 36897520
The present study aimed to further characterize fingolimod's safety profile, and to assess the patient-reported treatment satisfaction and impact of fingolimod on the quality of life (QoL) of patients with multiple sclerosis (MS) treated in routine care in Greece. METHODS: …
The present study aimed to further characterize fingolimod's safety profile, and to assess the patient-reported treatment satisfaction and i …
Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial.
Monk BJ, Tewari KS, Dubot C, Caceres MV, Hasegawa K, Shapira-Frommer R, Salman P, Yañez E, Gümüş M, Hurtado de Mendoza MO, Samouëlian V, Castonguay V, Arkhipov A, Tekin C, Li K, Martin Nguyen A, Monberg MJ, Colombo N, Lorusso D. Monk BJ, et al. Lancet Oncol. 2023 Apr;24(4):392-402. doi: 10.1016/S1470-2045(23)00052-9. Epub 2023 Mar 3. Lancet Oncol. 2023. PMID: 36878237 Clinical Trial.
Patients were randomly assigned (1:1) centrally by means of an interactive voice response system in a double-blind manner to receive either pembrolizumab 200 mg or placebo every 3 weeks intravenously for up to 35 cycles plus chemotherapy (paclitaxel 175 mg/m(2) plus cispla …
Patients were randomly assigned (1:1) centrally by means of an interactive voice response system in a double-blind manner to receive either …
Effects of the COVID-19 Pandemic on Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Diseases: COPANMO(G)-Study.
Hümmert MW, Bütow F, Tkachenko D, Ayzenberg I, Pakeerathan T, Hellwig K, Klotz L, Häußler V, Stellmann JP, Warnke C, Goereci Y, Etgen T, Luessi F, Bronzlik P, Gingele S, Lauenstein AS, Kleiter I, Rommer PS, Paul F, Bellmann-Strobl J, Duchow A, Then Bergh F, Pul R, Walter A, Pellkofer H, Kümpfel T, Pompsch M, Kraemer M, Albrecht P, Aktas O, Ringelstein M, Senel M, Giglhuber K, Berthele A, Jarius S, Wildemann B, Trebst C; Neuromyelitis Optica Study Group (NEMOS). Hümmert MW, et al. Neurol Neuroimmunol Neuroinflamm. 2023 Jan 24;10(2):e200082. doi: 10.1212/NXI.0000000000200082. Print 2023 Mar. Neurol Neuroimmunol Neuroinflamm. 2023. PMID: 36693760 Free PMC article.
Health-related quality of life (HRQoL) was measured with the EuroQoL Group 5-Dimension 5-Level Scale (EQ-5D-5L). Demographic and clinical characteristics were retrieved from the NEMOS database. ...The reported HRQoL did not decline compared with a prepandemic assessment (m …
Health-related quality of life (HRQoL) was measured with the EuroQoL Group 5-Dimension 5-Level Scale (EQ-5D-5L). Demographic and clin …
Knee function, quality of life, pain, and living conditions after distal femoral resection knee arthroplasty for non-tumor indications.
Corap Y, Brix M, Brandt JR, Emmeluth C, Lindberg-Larsen M. Corap Y, et al. BMC Musculoskelet Disord. 2023 Jan 6;24(1):9. doi: 10.1186/s12891-022-06104-z. BMC Musculoskelet Disord. 2023. PMID: 36609249 Free PMC article.
RESULTS: The mean age was 67.9 years (SD 13.6), and 21 (70%) were female. Mean total Oxford Knee Score was 29.9 (SD 10.5), mean Copenhagen Knee ROM flexion was 116 (SD 21.6), and mean extension was - 2 (SD10.1). Mobility aids were used by 18 (60%) patients, i.e. a cane (30 …
RESULTS: The mean age was 67.9 years (SD 13.6), and 21 (70%) were female. Mean total Oxford Knee Score was 29.9 (SD 10.5), mean Copen …
Family Caregivers of People with Dementia Associate with Poor Health-Related Quality of Life: A Nationwide Population-Based Study.
Shin JH, Kim JH. Shin JH, et al. Int J Environ Res Public Health. 2022 Dec 5;19(23):16252. doi: 10.3390/ijerph192316252. Int J Environ Res Public Health. 2022. PMID: 36498333 Free PMC article.
Caregivers had lower index scores and higher frequency of some/extreme problems in all five dimensions of the EQ-5D compared with noncaregivers. Logistic regression adjusting for potential confounding factors found that caregivers had a higher frequency of poor HRQoL (lowe …
Caregivers had lower index scores and higher frequency of some/extreme problems in all five dimensions of the EQ-5D compared with non …
Engagement in volunteering activities by persons with multiple sclerosis in Switzerland.
Mettler M, Stanikić M, Schwegler U, Sieber C, Ajdacic-Gross V, Rodgers S, Haag C, Zecca C, Calabrese P, Kägi S, Rapold I, von Wyl V; Swiss Multiple Sclerosis Registry (SMSR). Mettler M, et al. Mult Scler Relat Disord. 2023 Jan;69:104427. doi: 10.1016/j.msard.2022.104427. Epub 2022 Nov 24. Mult Scler Relat Disord. 2023. PMID: 36470169 Free article.
Sociodemographic, health-, work- and daily activity-related factors were included in the analysis. RESULTS: About one third (29.4%) of participants reported engagement in volunteering activities, most often through charities (16.02%) and cultural organizations (14.36%). .. …
Sociodemographic, health-, work- and daily activity-related factors were included in the analysis. RESULTS: About one third (29.4%) o …
The efficacy and safety of intravesical chondroitin sulphate solution in recurrent urinary tract infections.
Rahnama'i MS, Javan Balegh Marand A, Röschmann-Doose K, Steffens L, Arendsen HJ. Rahnama'i MS, et al. BMC Urol. 2022 Nov 23;22(1):188. doi: 10.1186/s12894-022-01149-7. BMC Urol. 2022. PMID: 36424583 Free PMC article.
Patients filled in a standardized quality of life questionnaire (EQ-5D). RESULTS: We found a statistically significant reduction of number of infections from 7.10 0.50 SEM to 0.45 0.07 SEM after 12 months therapy with CS compared to 12 months therapy with LDLTAB (from 7.04 …
Patients filled in a standardized quality of life questionnaire (EQ-5D). RESULTS: We found a statistically significant reduction of n …
98 results